



Mean Platelet Volume (MPV) as a Predictor of Infarct Related Artery Patency in Patients with ST-segment Elevation Myocardial Infarction Receiving Thrombolytic Therapy

Thesis

Submitted for partial fulfillment of Master Degree in
Cardiology

By

Sherif Mohamed Mahmoud Abu Elenin

M.B.,B.Ch.

Supervised by

**PROF. DR. ADEL MOHAMED KAMAL EL
ETRIBY**

Professor of Cardiology

Faculty of Medicine - Ain Shams University

DR. MOHAMED ABDELZAHER ABDALLAH

Lecturer of Cardiology

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

Cairo - ٢٠١٢

Acknowledgment

I would like to thank God almighty for every word I have learned through this thesis, and for his guidance, support, mercifulness and to whom I relate my success in my all life.

*Although no words can express my deep thanks & gratitude to my supervisors, I'd like to thank **DR. ADEL ELETRIBY** (Head of department of Cardiology – Ain Shams University), **DR. MOHAMED ABDELZAHER** (Lecturer of Cardiology – Ain Shams university), to whom I owe more than words can express for their priceless patience, encouragement and support.*

It is of great honor to work under their guidance and close supervision. They generously gave me in every step to put this work in its best form.

I am also deeply indebted for my family especially my wife and my sister for their support, patience and encouragement.

Sherif Mohamed Mahmoud Abu Elenin



متوسط حجم الصفائح الدموية (MPV)
باعتباره أحد وسائل التنبؤ بمعدل سريان
الدم في الشرايين التاجية بين المرضى الذين
يعانون من احتشاء بعضلة القلب مصحوب
بارتفاع جزء ST

رسالة
تمهيداً للحصول علي درجة الماجستير في
القلب و الأوعية الدموية

مقدمة من

طبيب/ شريف محمد محمود ابوالعنين
بكالوريوس الطب والجراحة العامة


تحت إشراف

أ.د / عادل محمد كمال الإتربي
أستاذ القلب والأوعية الدموية
كلية الطب- جامعة عين شمس

د. / محمد عبد الظاهر عبد الله
مدرس القلب والأوعية الدموية
كلية الطب- جامعة عين شمس

كلية الطب
جامعة عين شمس

القاهرة ٢٠١٢



II

وَقُلْ رَبِّ
زِدْنِي

و

سورة طه (١١٤)

CONTENTS

	Page
 LIST OF ABBREVIATIONS	ii
 LIST OF TABLES	iv
 LIST OF FIGURES	v
 INTRODUCTION.....	١
 AIM OF THE WORK	٣
 REVIEW OF LITERATURE	٤
* Chapter ١: Myocardial infarction	٤
* Chapter ٢: platelet	٤٤
 PATIENTS AND METHODS	٦٤
 RESULTS.....	٦٨
 DISCUSSION.....	٨٨
 CONCLUSION	٩٣
 REFERENCES.....	٩٤
 SUMMARY	١٠٧
 MASTER TABLE	١١٠
 ARABIC SUMMARY.....	-

LIST OF ABBREVIATIONS

ACEI	Angiotensin converting enzyme inhibitors
ADP	Adenosine diphosphate
AMI	Acute myocardial infarction
BBB	bundle branch block
CABG	Coronary artery bypass grafting
CBC	complete blood count
CK	Creatine kinase
D•W	Dextrose o% in water
DBP	diastolic blood pressure
DM	diabetes mellitus
DMS	Demarcation membrane system
ECG	Electrocardiogram
ED	Emergency department
EDTA	Ethylenediaminetetraacetic acid
EMS	Emergency medical services
FL	Femtoliter
HTN	Hypertension
LBBS	Left bundle branch block
LD	Lactate dehydrogenase
LDL	Low density lipoprotein
EMS	Emergency medical system
MI	Myocardial infarction
MPV	Mean platelet volume
mRNA	messenger RNA
MINAP	Myocardial Infarction National Audit Programme
n-PA	Lanoteplase

NPV	Negative predictive value
NSTEMI	Non ST-segment elevation myocardial infarction
PCI	Percutaneous coronary intervention
PPV	Positive predictive value
PTCA	Percutaneous transluminal coronary angioplasty
r-PA	Retenplase
RBBB	right bundle branch block
SAP	stable angina pectoris
SCF	slow coronary flow
SD	standard deviation
SK	Streptokinase
STEMI	ST-segment elevation myocardial infarction
TIMI	Thrombolysis in myocardial infarction
TAFI	Thrombin-activatable fibrinolysis inhibitor
TNK	Tenecteplase
tPA	Tissue plasminogen activator
TPO	Thrombopoietin
TXAν	Thromboxane A ν
UFH	Unfractionated heparin
UK	Urokinase
USAP	Unstable angina pectoris
URL	Upper reference limit

LIST OF TABLES

Table No.	Title	Page
١	Biomarkers for the Evaluation of Patients with ST-Elevation Myocardial Infarction.....	٢٢
٢	Preferred reperfusion strategy for STEMI.....	٣١
٣	Fibrinolytic agents.....	٣٥
٤	Distribution of the studied cases as regard demographic data	٦٨
٥	Distribution of the studied cases as regard history	٦٩
٦	Distribution of the studied cases as regard examination	٧٠
٧	Distribution of the studied cases as regard ECG findings.....	٧١
٨	Distribution of the studied cases as regard laboratory data at admission.....	٧٢
٩	Distribution of the studied cases as regard Echo data	٧٣
١٠	Distribution of the studied cases as regard angiographic data	٧٤
١١	Relationship between MPV versus general data among the studied group	٧٥
١٢	Relation between MPV versus past history among the studied group.....	٧٥
١٣	Correlation between MPV versus different variables.....	٧٦
١٤	Correlation between MPV versus non laboratory Variables.....	٧٩
١٥	Correlation between MPV versus different variables by multiple	٨٣
١٦	Relation between MPV versus IRA among the studied group	٨٤
١٧	Relation between MPV versus motion abnormalities and valvular lesion	٨٥
١٨	Validity of MPV and platelets in prediction of IRA patency.....	٨٦

LIST OF FIGURES

Fig. No.	Title	Page
١	Stages of endothelial dysfunction in atherosclerosis	٨
٢	Blood coagulation	٩
٣	Obstruction of a coronary artery by a thrombus overlying atherosclerotic plaque	١٠
٤	Schematic representation of the progression of myocardial necrosis after coronary artery occlusion	١١
٥	Atherosclerotic plaque and plaque rupture	١٢
٦	Acute Myocardial Infarction is precipitated	١٤
٧	ST segment changes in MI	٢٠
٨	Plot of the appearance of cardiac markers in blood versus time after onset of symptoms	٢٣
٩	Options for Transportation of STEMI Patients and Initial Reperfusion Treatment Goals	٢٦
١٠	The fibrinolytic mechanisms	٣٢
١١	Percentage of patients receiving thrombolytic therapy	٤٠
١٢	Mechanisms proposed for platelet production	٤٦
١٣	Megakaryocyte production of platelets	٤٩
١٤	Platelet morphology	٥٠
١٥	Model of α β integrin receptor	٥٧
١٦	The Sysmex pocH-١٠٠ i	٦٥
١٧	Gender distribution of the studied cases	٦٩
١٨	Distribution of the studied cases as regard history	٧٠
١٩	Distribution of the studied cases as regard TIMI flow	٧٤
٢٠	Correlation between MPV and Killip classification	٧٧
٢١	Correlation between MPV and CK level	٧٧
٢٢	Correlation between MPV and LDH level	٧٨

२३	Correlation between MPV and TIMI flow	१०
२४	Correlation between MPV and EF%	१०
२५	Correlation between MPV and LVESD	११
२६	Correlation between MPV and LVEDD.....	११
२७	Correlation between MPV and Number of vessels.....	१२
२८	Significant difference between MPV to IRA patency	१४
२९	Specificity and sensitivity of MPV and platelets (PLT).....	१७

INTRODUCTION

Despite impressive strides in diagnosis and management over the past decade, acute MI continues to be a major public health problem in the developing countries as well as in the developed world. In the United States more than 1 million people each year suffer an acute MI. Two hundred to three hundred thousands are estimated to die of acute MI before hospitalization. An American has an acute MI every 29 seconds and someone dies of an acute MI every minute (*Chockalingam et al, 2011*).

The modern reperfusion era of coronary care was introduced by intracoronary and then intravenous thrombolysis, increased use of aspirin, and development of primary percutaneous transluminal coronary angioplasty (PTCA), and implantation of coronary stent for MI. These reperfusion strategies contributed to a significant decline in mortality from AMI (*Chockalingam et al, 2011*).

Efforts made within the last decade for finding the most efficacious fibrinolytic regimen in the ST-segment elevation acute myocardial infarction (STEMI) have resulted in the testing of more rapid regimens of alteplase (also known as tissue plasminogen activator or tPA) and of a new generation of tPA derivatives (reteplase, lanoteplase and tenecteplase) in combination with unfractionated heparin (UFH), enoxaparin, hirulog or abciximab (*Ross A.M, et al, 2011*).

However, although a significant increase in the Thrombolysis in Myocardial Ischemia (TIMI) grade 3 of coronary reperfusion was reported with the new regimens, this apparent benefit did not lead to a significant reduction in mortality. Except for the GUSTO-I trial, none of the trials comparing two or more thrombolytic regimens demonstrated the superiority of any regimen in reducing mortality (*Simoons M, et al, 1999*).

AIM OF THE WORK

This study was addressed to investigate the correlation between mean platelet volume (MPV) and infarct related artery patency in patient with ST-segment elevation myocardial infarction receiving thrombolytic therapy.

CHAPTER (1)

MYOCARDIAL INFARCTION

Epidemiology:

Coronary heart disease is the leading cause of death worldwide, with myocardial infarction a common manifestation of this disease. The estimated annual incidence of MI in the United States (including both STEMI and NSTEMI) is 600,000 new and 320,000 recurrent attacks. In 2014, AMI resulted in 690,000 hospital stays and \$31 billion in hospital charges (*Russo and Andrews, 2016*).

The risk of further cardiovascular complications, including recurrent MI, sudden cardiac death, heart failure, stroke and angina pectoris, for those who survive acute myocardial infarction (AMI) is substantial (*Rosamond et al., 2010*).

Definition:

The term myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Under these conditions anyone of the following criteria meets the diagnosis of myocardial infarction:

- Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile of the upper reference limit (URL) together with

evidence of myocardial ischemia with at least one of the following:

- Symptoms of ischemia;
 - ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch block (LBBB));
 - Development of pathological Q waves on the ECG;
 - Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
- Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischemia, and accompanied by presumably new ST elevation, or new LBBB, and/or evidence of fresh thrombus by coronary angiography and/or at autopsy, but death occurring before blood samples could be obtained, or at a time before the appearance of cardiac biomarkers in the blood.
 - For percutaneous coronary intervention (PCI) in patients with normal baseline troponin values, elevations of cardiac biomarkers above the 99th percentile URL are indicative of peri-procedural myocardial necrosis. By convention, increases of biomarkers 3 times greater than 99th percentile URL have been designated as defining PCI-related myocardial infarction. A subtype related to a documented stent thrombosis is recognized.